- Israel-Based Clearmind (CMND) adds additional results from the third part of its pre-clinical study for cocaine addiction treatment
- Clearmind’s primary objective is to research and develop psychedelic-based compounds
- The results suggest that MEAI may be effective in treating substance addiction without interrupting the natural reward process
- The drug demonstrated a unique ability to decrease cocaine craving and potentially become the first dedicated cocaine addiction treatment
- The purpose of this in-vivo study was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards
- Clearmind Medicine (CMND) is down 18.99 per cent, trading at C$5.12 at 11:14 pm EST
Clearmind Medicine (CMND) found additional pre-clinical results in its research studies of MEAI and its effect on substance use disorder.
The latest in-vivo studies examined the effect of MEAI on the natural reward proforns to cocaine addiction.
Professor Gal Yadid led studies from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel.
The proprietary MEAI, at a dose of 5mg/kg, found a unique ability to decrease cocaine cravings and potentially become the first dedicated cocaine addiction treatment.
The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species.
This in-vivo study aimed to conclude whether MEAI uses the same mechanisms that underlie seeking drugs and natural rewards (such as sucrose).
Results found that natural reward was maintained in the MEAI-treated rats.
In the end, results showed that the effect of MEAI on drug-seeking is not related to the general reward system.
Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer, commented on the clinical study.
“The results of these latest in-vivo studies reinforce previous findings and demonstrate that MEAI may be an effective treatment addiction without negatively affecting natural reward.”
“Cocaine is extremely addictive, and there is currently no dedicated treatment. I believe Clearmind is leading the way in this field,” added Dr. Zuloff-Shani.
Professor Gal Yadid added, “The empirical data show that MEAI is a potential treatment for cocaine addiction, in particular, and SUD, in general.”
“Further studies are needed to better characterize the responding population,” concluded Professor Yadid.
Clearmind is a psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
Its primary objective is to research and develop psychedelic-based compounds while attempting to commercialize them as regulated medicines, foods or supplements.
Clearmind Medicine (CMND) is down 18.99 per cent, trading at C$5.12 at 11:14 pm EST.
